2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines by Tracy, Cynthia M. et al.
Tracy et al Clinical Guidelines2012 ACCF/AHA/HRS focused update of the 2008 guidelines for
device-based therapy of cardiac rhythm abnormalitiesA report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice
Guidelines
Developed in collaboration with The American Association for Thoracic Surgery, Heart Failure Society of
America, and Society of Thoracic Surgeons2012
Writing
Group
Members*:*Writing group member
which their specific r
Appendix 1 for recus
Society Representativ
son. kAmerican Assoc
racic Surgeons Repre
**ACCF/AHATask F
This document was app
Board of Trustees, the
nating Committee, an
The American College o
as follows: Tracy CM
III, Ferguson TB Jr,
MH, Shanker AJ, Si
ACCF/AHA/HRS foc
of cardiac rhythm ab
Foundation/American
Thorac Cardiovasc SCynthia M. Tracy, MD, FACC, FAHA, Chair,* Andrew E. Epstein, MD, FACC, FAHA, FHRS,
Vice Chair,* Dawood Darbar, MD, FACC, FHRS,y John P. DiMarco, MD, PhD, FACC, FHRS,*,z
Sandra B. Dunbar, RN, DSN, FAAN, FAHA,yN.A.Mark Estes III, MD, FACC, FAHA, FHRS,*,x
T. Bruce Ferguson, Jr, MD, FACC, FAHA,*,k,{ Stephen C. Hammill, MD, FACC, FHRS,z
Pamela E. Karasik, MD, FACC, FHRS,y Mark S. Link, MD, FACC, FHRS,*,y
Joseph E. Marine, MD, FACC, FHRS,y Mark H. Schoenfeld, MD, FACC, FAHA, FHRS,*,y
Amit J. Shanker, MD, FACC, FHRS,z Michael J. Silka, MD, FACC,y
Lynne Warner Stevenson, MD, FACC,*,# William G. Stevenson, MD, FACC, FAHA,
FHRS,*,** and Paul D. Varosy, MD, FACC, FHRSy2008
Writing
Committee
Members:Andrew E. Epstein, MD, FACC, FAHA, FHRS, Chair, John P. DiMarco, MD, PhD, FACC,
FHRS, Kenneth A. Ellenbogen, MD, FACC, FAHA, FHRS, N. A. Mark Estes III, MD, FACC,
FAHA, FHRS, Roger A. Freedman, MD, FACC, FHRS, Leonard S. Gettes, MD, FACC, FAHA,
A. Marc Gillinov, MD, FACC, FAHA, Gabriel Gregoratos, MD, FACC, FAHA,
Stephen C. Hammill, MD, FACC, FHRS, David L. Hayes, MD, FACC, FAHA, FHRS,
Mark A. Hlatky, MD, FACC, FAHA, L. Kristin Newby, MD, FACC, FAHA,
Richard L. Page, MD, FACC, FAHA, FHRS, Mark H. Schoenfeld, MD, FACC, FAHA, FHRS,
Michael J. Silka, MD, FACC, Lynne Warner Stevenson, MD, FACC, and
Michael O. Sweeney, MD, FACCACCF/AHA
Task Force
Members:Jeffrey L. Anderson, MD, FACC, FAHA, Chair, Alice K. Jacobs, MD, FACC, FAHA, Immediate
Past Chair, Jonathan L. Halperin, MD, FACC, FAHA, Chair-Elect, Nancy M. Albert, PhD,
CCNS, CCRN, Mark A. Creager, MD, FACC, FAHA, David DeMets, PhD,
Steven M. Ettinger, MD, FACC, Robert A. Guyton, MD, FACC, Judith S. Hochman, MD, FACC,
FAHA, Frederick G. Kushner, MD, FACC, FAHA, E. Magnus Ohman, MD, FACC,
William Stevenson, MD, FACC, FAHA, and Clyde W. Yancy, MD, FACC, FAHASupplemental material is available online.s are required to recuse themselves from voting on sections to
elationships with industry and other entities may apply; see
al information. yACCF/AHA Representative. zHeart Rhythm
e. xACCF/AHATask Force on Performance Measures Liai-
iation for Thoracic Surgery Representative. {Society of Tho-
sentative. #Heart Failure Society of America Representative.
orce on Practice Guidelines Liaison.
roved by the American College of Cardiology Foundation
American Heart Association Science Advisory and Coordi-
d the Heart Rhythm Society Board of Trustees in May 2012.
f Cardiology Foundation requests that this document be cited
, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes NAM
Hammill SC, Karasik PE, Link MS, Marine JE, Schoenfeld
lka MJ, Stevenson LW, Stevenson WG, Varosy PD. 2012
used update of the 2008 guidelines for device-based therapy
normalities: a report of the American College of Cardiology
Heart Association Task Force on Practice Guidelines. J
urg. 2012;144:e127-45.
This article is copublished inCirculation,Heart Rhythm, and Journal of the American
College of Cardiology.
Copies: This document is available on the World Wide Web sites of the American
College of Cardiology (www.cardiosource.org), the American Heart Association
(my.americanheart.org), and the Heart Rhythm Society (www.hrsonline.org). For
copies of this document, please contact Elsevier Inc. Reprint Department, fax
(212) 633-3820, E-mail reprints@elsevier.com.
Permissions: Multiple copies, modification, alteration, enhancement, and/or distribu-
tion of this document are not permitted without the express permission of the
American College of Cardiology Foundation. Please contact Elsevier’s permission
department at healthpermissions@elsevier.com.
0022-5223/$36.00
Copyright 2012 by The American Association for Thoracic Surgery, the American
College of Cardiology Foundation, the American Heart Association, Inc, and the
Heart Rhythm Society.
http://dx.doi.org/10.1016/j.jtcvs.2012.08.032
The Journal of Thoracic and Cardiovascular Surgery c Volume 144, Number 6 e127
Clinical Guidelines Tracy et alTABLE OF CONTENTS
Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e128
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e130
1.1. Methodology and Evidence Review . . . . . . . . . . . . e130
1.2. Organization of the Writing Group . . . . . . . . . . . . . e131
1.3. Document Review and Approval . . . . . . . . . . . . . . e131
1.4. Scope of the Focused Update . . . . . . . . . . . . . . . . . e131
2. Indications for Pacing . . . . . . . . . . . . . . . . . . . . . . . . .e132
2.4. Pacing for Hemodynamic Indications . . . . . . . . . . . e132
2.4.1. Cardiac Resynchronization Therapy . . . . .e132
2.8. Pacemaker Follow-up . . . . . . . . . . . . . . . . . . . . . . . e136
2.8.3. Remote Follow-up and Monitoring . . . . . .e136
Presidents and Staff . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e137
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e137
Appendix 1 Author relationships with industry and other
entities (relevant)—2012 ACCF/AHA/HRS
focused update of the 2008 guidelines for
device-based therapy of cardiac rhythm
abnormalities . . . . . . . . . . . . . . . . . . . . . . . . .e140
Appendix 2 Reviewer relationships with industry and other
entities (relevant)—2012 ACCF/AHA/HRS
focused update of the 2008 guidelines for
device-based therapy of cardiac rhythm
abnormalities . . . . . . . . . . . . . . . . . . . . . . . . .e142
Appendix 3 Indications for CRT therapy—algorithm . . .e145
PREAMBLE
Keeping pace with the stream of new data and evolving ev-
idence on which guideline recommendations are based is an
ongoing challenge to timely development of clinical prac-
tice guidelines. In an effort to respond promptly to new ev-
idence, the American College of Cardiology Foundation
(ACCF)/American Heart Association (AHA) Task Force
on Practice Guidelines (Task Force) has created a ‘‘focused
update’’ process to revise the existing guideline recommen-
dations that are affected by evolving data or opinion. New
evidence is reviewed in an ongoing fashion to more effi-
ciently respond to important science and treatment trends
that could have a major impact on patient outcomes and
quality of care. Evidence is reviewed at least twice a year,
and updates are initiated on an as-needed basis and com-
pleted as quickly as possible while maintaining the rigorous
methodology that the ACCF and AHA have developed dur-
ing their partnership of>20 years.
These focused updates are prompted following a thor-
ough review of late-breaking clinical trials presented at na-
tional and international meetings, in addition to other new
published data deemed to have an impact on patient care
(Section 1.1, ‘‘Methodology and Evidence Review’’).
Through a broad-based vetting process, the studies in-
cluded are identified as being important to the relevant pa-
tient population. The focused update is not intended to
be based on a complete literature review from the date of
the previous guideline publication but rather to includee128 The Journal of Thoracic and Cardiovascular Surpivotal new evidence that may affect changes to current
recommendations.
Specific criteria or considerations for inclusion of new
data include the following:
 publication in a peer-reviewed journal;
 large, randomized, placebo-controlled trial(s);
 nonrandomized data deemed important on the basis
of results affecting current safety and efficacy as-
sumptions, including observational studies and meta-
analyses;
 strength/weakness of research methodology and findings;
 likelihoodof additional studies influencing current findings;
 impact on current and/or likelihood of need to develop
new performance measure(s);
 request(s) and requirement(s) for review and update from
the practice community, key stakeholders, and other
sources free of industry relationships or other potential
bias;
 number of previous trials showing consistent results; and
 need for consistency with a new guideline or guideline
updates or revisions.
In analyzing the data and developing recommendations
and supporting text, the writing group uses evidence-
based methodologies developed by the Task Force.1 The
Class of Recommendation (COR) is an estimate of the
size of the treatment effect, with consideration given to risks
versus benefits, as well as evidence and/or agreement that
a given treatment or procedure is or is not useful/effective
and in some situations may cause harm. The Level of Evi-
dence (LOE) is an estimate of the certainty or precision of
the treatment effect. The writing group reviews and ranks
evidence supporting each recommendation, with the weight
of evidence ranked as LOE A, B, or C, according to specific
definitions that are included in Table 1. Studies are identi-
fied as observational, retrospective, prospective, or random-
ized, as appropriate. For certain conditions for which
inadequate data are available, recommendations are based
on expert consensus and clinical experience and are ranked
as LOE C. When recommendations at LOE C are supported
by historical clinical data, appropriate references (including
clinical reviews) are cited if available. For issues for which
sparse data are available, a survey of current practice among
the clinicians on the writing group is the basis for LOE C
recommendations, and no references are cited. The schema
for COR and LOE is summarized in Table 1, which also pro-
vides suggested phrases for writing recommendations
within each COR. A new addition to this methodology is
separation of the Class III recommendations to delineate
whether the recommendation is determined to be of ‘‘no
benefit’’ or is associated with ‘‘harm’’ to the patient. In ad-
dition, in view of the increasing number of comparative
effectiveness studies, comparator verbs and suggested
phrases for writing recommendations for the comparativegery c December 2012
TABLE 1. Applying classification of recommendations and level of evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend
themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective. *Data
available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction,
history of heart failure, and prior aspirin use. yFor comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of
comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.
Tracy et al Clinical Guidelineseffectiveness of one treatment or strategy versus another
have been added for COR I and IIa, LOE A or B only.
In view of the advances in medical therapy across the
spectrum of cardiovascular diseases, the Task Force has
designated the term guideline-directed medical therapy
(GDMT) to represent optimal medical therapy as defined
by ACCF/AHA guideline (primarily Class I)–recommen-
ded therapies. This new term, GDMT, will be used herein
and throughout all future guidelines.
Because the ACCF/AHA practice guidelines address pa-
tient populations (and health care providers) residing inThe Journal of Thoracic and CarNorth America, drugs that are not currently available in
North America are discussed in the text without a specific
COR. For studies performed in large numbers of subjects
outside North America, each writing group reviews the po-
tential impact of different practice patterns and patient pop-
ulations on the treatment effect and relevance to the ACCF/
AHA target population to determine whether the findings
should inform a specific recommendation.
The ACCF/AHA practice guidelines are intended to as-
sist health care providers in clinical decision making by de-
scribing a range of generally acceptable approaches to thediovascular Surgery c Volume 144, Number 6 e129
Clinical Guidelines Tracy et aldiagnosis, management, and prevention of specific diseases
or conditions. The guidelines attempt to define practices
that meet the needs of most patients in most circumstances.
The ultimate judgment about care of a particular patient
must be made by the health care provider and patient in light
of all the circumstances presented by that patient. As a re-
sult, situations may arise in which deviations from these
guidelines may be appropriate. Clinical decision making
should consider the quality and availability of expertise in
the area where care is provided. When these guidelines
are used as the basis for regulatory or payer decisions, the
goal should be improvement in quality of care. The Task
Force recognizes that situations arise in which additional
data are needed to inform patient care more effectively;
these areas will be identified within each respective guide-
line when appropriate.
Prescribed courses of treatment in accordance with these
recommendations are effective only if they are followed.
Because lack of patient understanding and adherence may
adversely affect outcomes, physicians and other health
care providers should make every effort to engage the pa-
tient’s active participation in prescribed medical regimens
and lifestyles. In addition, patients should be informed of
the risks, benefits, and alternatives to a particular treatment
and should be involved in shared decision making whenever
feasible, particularly for COR IIa and IIb, for which the
benefit-to-risk ratio may be lower.
The Task Force makes every effort to avoid actual, poten-
tial, or perceived conflicts of interest that may arise as a re-
sult of industry relationships or personal interests among the
members of the writing group. All writing group members
and peer reviewers of the guideline are required to disclose
all current health care–related relationships, including those
existing 12 months before initiation of the writing effort. In
December 2009, the ACCF and AHA implemented a new
policy for relationships with industry and other entities
(RWI) that requires the writing group chair plus a minimum
of 50% of the writing group to have no relevant RWI
(Appendix 1 includes the ACCF/AHA definition of rele-
vance). These statements are reviewed by the Task Force
and all members during each conference call and/or meet-
ing of the writing group and are updated as changes occur.
All guideline recommendations require a confidential vote
by the writing group and must be approved by a consensus
of the voting members. Members are not permitted to draft
or vote on any text or recommendations pertaining to their
RWI. Members who recused themselves from voting are in-
dicated in the list of writing group members, and specific
section recusals are noted in Appendix 1. Authors’ and
peer reviewers’ RWI pertinent to this guideline are dis-
closed in Appendices 1 and 2, respectively. Additionally,
to ensure complete transparency, writing group members’
comprehensive disclosure information—including RWI
not pertinent to this document—is available as an onlinee130 The Journal of Thoracic and Cardiovascular Sursupplement. Comprehensive disclosure information for
the Task Force is also available online at www.
cardiosource.org/ACC/About-ACC/Leadership/Guidelines-
and-Documents-Task-Forces.aspx. The work of the writing
group is supported exclusively by the ACCF, AHA, and the
Heart Rhythm Society (HRS) without commercial support.
Writing group members volunteered their time for this
activity.
In an effort to maintain relevance at the point of care for
practicing physicians, the Task Force continues to oversee
an ongoing process improvement initiative. As a result, in
response to pilot projects, several changes to these guide-
lines will be apparent, including limited narrative text, a fo-
cus on summary and evidence tables (with references linked
to abstracts in PubMed), and more liberal use of summary
recommendation tables (with references that support
LOE) to serve as a quick reference.
In April 2011, the Institute of Medicine released 2 re-
ports: Finding What Works in Health Care: Standards for
Systematic Reviews and Clinical Practice Guidelines We
Can Trust.2,3 It is noteworthy that the ACCF/AHA
practice guidelines were cited as being compliant with
many of the standards that were proposed. A thorough
review of these reports and our current methodology is
under way, with further enhancements anticipated.
The recommendations in this focused update are consid-
ered current until they are superseded in another focused
update or the full-text guideline is revised. Guidelines are
official policy of both the ACCF and AHA.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines1. INTRODUCTION
1.1. Methodology and Evidence Review
Late-breaking clinical trials presented at the annual sci-
entific meetings of the ACC, AHA, HRS, and European So-
ciety of Cardiology (2008 through 2010), as well as other
selected data reported through January 2012, were reviewed
by the guideline writing group along with the Task Force
and other experts to identify trials and other key data that
might affect guideline recommendations. On the basis of
the criteria and considerations noted previously (Preamble),
recently published trial data and other clinical information
were considered important enough to prompt a focused up-
date of the ‘‘ACC/AHA/HRS 2008 Guidelines for Device-
Based Therapy of Cardiac Rhythm Abnormalities.’’4
To provide clinicians with a comprehensive set of data,
the absolute risk difference and number needed to treat or
harm, if they were published and their inclusion was
deemed appropriate, are provided in the guideline, along
with confidence intervals (CIs) and data related to the rela-
tive treatment effects, such as odds ratio, relative risk (RR),
hazard ratio (HR), or incidence rate ratio.gery c December 2012
Tracy et al Clinical GuidelinesConsult the full-text version of the ‘‘ACC/AHA/HRS
2008 Guidelines for Device-Based Therapy of Cardiac
Rhythm Abnormalities’’ for policy on clinical areas not
covered by the focused update.4 The individual recommen-
dations in this focused update will be incorporated into fu-
ture revisions or updates of the full-text guideline.
1.2. Organization of the Writing Group
For this focused update, selected members of the 2008
Device-Based Therapy (DBT) Writing Committee were in-
vited to participate on the basis of areas of expertise, re-
quirements for committee rotation, and the current RWI
policy; thosewho agreed are referred to as the 2012 Focused
UpdateWriting Group. The HRS was invited to be a partner
on this focused update and has provided representation. The
writing group also included representatives from the Amer-
ican Association for Thoracic Surgery, Heart Failure Soci-
ety of America, and Society of Thoracic Surgeons.
1.3. Document Review and Approval
This document was reviewed by 2 official reviewers each
nominated by the ACCF, AHA, and HRS, as well as 1 re-
viewer each from the American Association for Thoracic
Surgery, Heart Failure Society of America, and Society of
Thoracic Surgeons, and 21 individual content reviewers.
All information on reviewers’ RWI was collected and dis-
tributed to the writing group and is published in this docu-
ment (Appendix 2).
This document was approved for publication by the gov-
erning bodies of the ACCF, AHA, and HRS and was en-
dorsed by the American Association for Thoracic Surgery,
Heart Failure Society of America, and Society of Thoracic
Surgeons.
1.4. Scope of the Focused Update
Studies relevant to the management of patients treated
with DBT for cardiac rhythm abnormalities were identified
and reviewed as described previously in Section 1.1,
‘‘Methodology and Evidence Review.’’ On the basis of
these data, the writing group determined that updates to
the 2008 guideline were necessary for cardiac resynchroni-
zation therapy (CRT) and device follow-up.
Many clinical circumstances come into question in
daily practice as to the appropriate use of implantable
cardioverter-defibrillator (ICD)/CRT devices. Many of
these clinical scenarios are both common and of great im-
portance but have not or cannot be addressed by multicenter
clinical trials, so many of these will be addressed in the
‘‘Appropriate Use Criteria (AUC) for Implantable
Cardioverter-Defibrillators and Cardiac Resynchronization
Therapy’’ document that is currently in development. Un-
like comprehensive guidelines, AUC documents blend
evidence-based information and clinical experience thatThe Journal of Thoracic and Carcan help guide allocation of health care resources, and
they focus on the most common patient scenarios for which
procedures may be considered. The AUC document will
help define when it is reasonable to perform a procedure
and, importantly, when it is not reasonable. Some of the sce-
narios included in the AUC may be outside guideline indi-
cations. As such, AUC are complementary to guidelines and
should be used in conjunction with them for determining
patient care. Furthermore, the ACCF and AHA are currently
undertaking a revision of the guidelines for management of
heart failure (HF). The DBTand HF guideline writing com-
mittees haveworked to maintain concordance on the recom-
mendations with regard to indications for CRT.
The writing group also thoroughly reviewed the follow-
ing sections from the 2008 DBT guideline4 and determined
that although some new information may be available, the
recommendations remain current.
1. Hypertrophic cardiomyopathy—The management
of hypertrophic cardiomyopathy is addressed in the
‘‘2011 ACCF/AHA Guideline for the Diagnosis and
Treatment of Hypertrophic Cardiomyopathy.’’5 In that
document, the indications for ICDs have been modified
on the basis of reassessment of significance of risk fac-
tors. The present writing group did not analyze the
source documents that led to these changes and refer
the reader to the ACCF/AHA Guideline for full discus-
sion of ICDs in hypertrophic cardiomyopathy.
2. Arrhythmogenic right ventricular dysplasia/cardio-
myopathy—The writing group reviewed all published
evidence since the publication of the 2008 DBT guide-
line related to arrhythmogenic right ventricular dyspla-
sia/cardiomyopathy and determined that no changes to
the current recommendations for ICD indications were
warranted.
3. Genetic arrhythmia syndromes—The writing group
acknowledges that recent guidelines and data suggest
that there may be a limited role for primary-prevention
ICDs in individuals with a genetically confirmed diagno-
sis of long QT but without symptoms.6-8 Nevertheless, it
is the consensus of this writing group that until more
definitive trials or studies are completed, further
refinement of criteria for ICD implantation in this
patient group would not be appropriate. Therefore, the
class of recommendations for ICD implantation in
asymptomatic patients with a genetically confirmed
mutation will remain unchanged.
4. Congenital heart disease—Aswith other forms of struc-
tural heart disease, there has been increased use of ICDs
for primary prevention of sudden cardiac death in patients
with congenital heart disease.4,9 Although randomized
clinical trials have not been performed, multiple
observational studies have consistently reported that
systemic ventricular dysfunction in patients withdiovascular Surgery c Volume 144, Number 6 e131
Clinical Guidelines Tracy et alcongenital heart disease is the risk factor most predictive
of subsequent sudden cardiac death or appropriate ICD
rescue.10-12 These studies support consideration of an
expanded role of ICDs in future revisions of the
guideline, provided that consistent benefit with the use
of ICDs in patients with congenital heart disease and
advanced ventricular dysfunction is demonstrated.
Nevertheless, the current recommendations are not
changed at this time. There remain insufficient data to
make specific recommendations about CRT in patients
with congenital heart disease.13
5. Primary electrical disease—The writing group re-
viewed all published evidence since the publication of
the 2008 DBT guideline related to primary electrical dis-
ease and determined that no changes were warranted in
the current recommendations for ICD indications with
regard to idiopathic ventricular fibrillation, short-QT
syndrome, Brugada syndrome, and catecholaminergic
polymorphic ventricular tachycardia.
6. Terminal care—Patients with cardiovascular implant-
able electronic devices (CIEDs) are living longer, with
more surviving to develop comorbid conditions such as
dementia or malignancy that may ultimately define their
clinical course. This was recognized in the terminal care
section of the 2008 DBT guideline. Recommendations
on management of CIEDs in patients nearing end of
life or requesting withdrawal of therapy were expanded
upon in 2 subsequent HRS expert consensus statements
in an effort to provide guidance to caregivers dealing
with this increasingly prevalent and difficult issue.14,152. INDICATIONS FOR PACING
2.4. Pacing for Hemodynamic Indications
Although most commonly used to treat or prevent abnor-
mal rhythms, pacing can alter the activation sequence in the
paced chambers, influencing regional contractility and he-
modynamics. These changes are frequently insignificant
clinically but can be beneficial or harmful in some condi-
tions. Pacing to decrease symptoms for patients with
obstructive hypertrophic cardiomyopathy is discussed
separately in the full-text guideline, Section 2.4.2,
‘‘Obstructive Hypertrophic Cardiomyopathy.’’
2.4.1. Cardiac Resynchronization Therapy
(See Table 2 and the Online Data Supplement for addi-
tional data on the trials that comprise the basis for the rec-
ommendations in this focused update.)
The present document proposes several changes in rec-
ommendations for CRT, compared with the 2008 document.
Themost significant changes are (1) limitation of the Class I
indication to patients with QRS duration 150 ms; (2)
limitation of the Class I indication to patients with left
bundle-branch block (LBBB) pattern; (3) expansion ofe132 The Journal of Thoracic and Cardiovascular SurClass I indication to New York Heart Association
(NYHA) class II (and with LBBB with QRS duration
150 ms); and (4) the addition of a Class IIb recommenda-
tion for patients who have left ventricular ejection fraction
(LVEF) 30%, ischemic etiology of HF, sinus rhythm,
LBBB with a QRS duration 150 ms, and NYHA class I
symptoms. These changes may have important implications
for patient selection in clinical practice, and the justification
for these changes is discussed in the following paragraphs.
Progression of left ventricular (LV) systolic dysfunction
to clinical HF is frequently accompanied by impaired elec-
tromechanical coupling, which may further diminish effec-
tive ventricular contractility. The most common disruptions
are prolonged atrioventricular conduction (first-degree
atrioventricular block) and prolonged interventricular con-
duction, most commonly LBBB. Prolonged interventricular
and intraventricular conduction causes regional mechanical
delay within the left ventricle that can result in reduced ven-
tricular systolic function, altered myocardial metabolism,
functional mitral regurgitation, and adverse remodeling
with ventricular dilatation.31 Prolongation of the QRS dura-
tion occurs in approximately one third of patients with ad-
vanced HF32,33 and has been associated with ventricular
electromechanical delay (‘‘dyssynchrony’’), as identified
by multiple sophisticated echocardiographic indices. QRS
duration and dyssynchrony both have been identified as
predictors of worsening HF, sudden cardiac death, and
total death.34
Modification of ventricular electromechanical delay
with multisite ventricular pacing (commonly called
‘‘biventricular pacing’’ or CRT) can improve ventricular
systolic function, reduce metabolic costs, ameliorate func-
tional mitral regurgitation, and, in some patients, induce
favorable remodeling with reduction of cardiac chamber
dimensions.35-37 Functional improvement has been
demonstrated for exercise capacity, with peak oxygen
consumption in the range of 1 to 2 mL/kg/min and a 50- to
70-meter increase in 6-minute walking distance, as well as
a 10-point or greater reduction of HF symptoms on the
105-point Minnesota Living with Heart Failure scale.16,38,39
Meta-analyses of initial clinical experiences and larger
subsequent trials of CRT confirmed an approximately
30% decrease in hospitalizations and a mortality rate ben-
efit of 24% to 36%.40 In the COMPANION (Comparison
of Medical Therapy, Pacing, and Defibrillation in Heart
Failure) trial (NYHA class III/IV HF, QRS duration>120
ms, and LVEF 35% on GDMT), GDMT was compared
to CRT pacing therapy without backup defibrillation
(CRT-Pacemaker) and to CRT therapy with defibrillation
backup (CRT-D).17 Both CRT-Pacemaker and CRT-D re-
duced the risk of the primary composite endpoint by ap-
proximately 20% as compared with GDMT alone. CRT-D
reduced the mortality rate by 36% compared with medical
therapy, but there was insufficient evidence to conclude thatgery c December 2012
TABLE 2. Recommendations for CRT in patients with systolic heart failure
2012 DBT Focused Update Recommendations Comments
Class I
1. CRT is indicated for patients who have LVEF less than or equal to 35%,
sinus rhythm, LBBB with a QRS duration greater than or equal to 150
ms, and NYHA class II, III, or ambulatory IV symptoms on GDMT.
(Level of Evidence: A for NYHA class III/IV16-19; Level of Evidence: B
for NYHA class II20,21)
Modified recommendation (specifying CRT in patients with LBBB of150
ms; expanded to include those with NYHA class II symptoms).
Class IIa
1. CRT can be useful for patients who have LVEF less than or equal to
35%, sinus rhythm, LBBB with a QRS duration 120 to 149 ms, and
NYHA class II, III, or ambulatory IV symptoms on GDMT.16-18,20-22
(Level of Evidence: B)
New recommendation
2. CRT can be useful for patients who have LVEF less than or equal to
35%, sinus rhythm, a non-LBBB pattern with a QRS duration greater
than or equal to 150 ms, and NYHA class III/ambulatory class IV
symptoms on GDMT.16-18,21 (Level of Evidence: A)
New recommendation
3. CRT can be useful in patients with atrial fibrillation and LVEF less than
or equal to 35% on GDMT if a) the patient requires ventricular pacing
or otherwise meets CRT criteria and b) AV nodal ablation or
pharmacologic rate control will allow near 100% ventricular pacing
with CRT.23-26,26a,48 (Level of Evidence: B)
Modified recommendation (wording changed to indicate benefit based on
ejection fraction rather than NYHA class; level of evidence changed from
C to B).
4. CRT can be useful for patients on GDMTwho have LVEF less than or
equal to 35% and are undergoing new or replacement device
placement with anticipated requirement for significant (>40%)
ventricular pacing.25,27-29 (Level of Evidence: C)
Modified recommendation (wording changed to indicate benefit based on
ejection fraction and need for pacing rather than NYHA class); class
changed from IIb to IIa).
Class IIb
1. CRT may be considered for patients who have LVEF less than or equal
to 30%, ischemic etiology of heart failure, sinus rhythm, LBBB with
a QRS duration of greater than or equal to 150 ms, and NYHA class I
symptoms on GDMT.20,21 (Level of Evidence: C)
New recommendation
2. CRT may be considered for patients who have LVEF less than or equal
to 35%, sinus rhythm, a non-LBBB pattern with QRS duration 120 to
149ms, and NYHA class III/ambulatory class IVon GDMT.21,30 (Level
of Evidence: B)
New recommendation
3. CRT may be considered for patients who have LVEF less than or equal
to 35%, sinus rhythm, a non-LBBB pattern with a QRS duration
greater than or equal to 150 ms, and NYHA class II symptoms on
GDMT.20,21 (Level of Evidence: B)
New recommendation
Class III: No Benefit
1. CRT is not recommended for patients with NYHA class I or II
symptoms and non-LBBB pattern with QRS duration less than 150
ms.20,21,30 (Level of Evidence: B)
New recommendation
2. CRT is not indicated for patients whose comorbidities and/or frailty
limit survival with good functional capacity to less than 1 year.19 (Level
of Evidence: C)
Modified recommendation (wording changed to include cardiac as well as
noncardiac comorbidities).
See Appendix 3, ‘‘Indications for CRT Therapy—Algorithm.’’ CRT, Cardiac resynchronization therapy; DBT, device-based therapy; GDMT, guideline-directed medical therapy;
LBBB, left bundle-branch block; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
Tracy et al Clinical GuidelinesCRT-Pacemaker was inferior to CRT-D. The CARE-HF
(Cardiac Resynchronization in Heart Failure) trial18 limited
subjects to a QRS duration>150 ms (89% of patients) or
QRS duration 120 to 150 ms with echocardiographic evi-
dence of dyssynchrony (11% of patients). It was the first
study to show a significant (36%) reduction in death rate
for resynchronization therapy unaccompanied by backup
defibrillation compared with GDMT.18The Journal of Thoracic and CarIn the present document, we give a Class I recommenda-
tion for CRT in patients with QRS duration 150 ms. The
differential classification seen in this document related to
QRS duration is based on the results of multiple analyses
of CRT benefit. The prevalence of mechanical dyssyn-
chrony has been documented in>40% of patients with
dilated cardiomyopathy and QRS duration>120 ms, and
is as high as 70% among patients with QRS durationdiovascular Surgery c Volume 144, Number 6 e133
Clinical Guidelines Tracy et al>150 ms and intraventricular mechanical delay, as
identified by several echocardiographic techniques.34,41
However, the aggregate clinical experience has
consistently demonstrated that a significant clinical
benefit from CRT is greatest among patients with QRS
duration>150 ms.42,43 In a meta-analysis of 5 trials involv-
ing 6501 patients, CRT significantly decreased the primary
endpoint of death or hospitalization for HF in patients with
QRS duration 150 ms (HR, 0.58; 95% CI, 0.50 to 0.68;
P< .00001) but not in patients with QRS duration<150
ms (HR, 0.95; 95%CI, 0.83 to 1.10; P¼ .51).42 In addition,
subgroup analyses from several studies have suggested that
a QRS duration<150 ms is a risk factor for failure to re-
spond to CRT therapy.43,44 The observed differential
benefit of CRT was seen across patients in NYHA classes
I through IV. It has not been possible to reliably identify
those with shorter QRS durations who may benefit.
Patients with shorter QRS durations who otherwise
qualify for CRT are afforded Class II recommendations in
these guidelines.
An additional difference in the present document com-
pared with the 2008 DBT guideline4 is the limitation of
the recommendation for Class I indication to patients with
LBBB pattern as compared to those with non-LBBB. For
patients with QRS duration 120 ms who do not have
a complete LBBB (non-LBBB patterns), evidence for ben-
efit with CRT is less compelling than in the presence of
LBBB.45-47 The impact of the specific QRS morphology
on clinical event reduction with CRT was evaluated in
a meta-analysis of 4 clinical trials including 5356 patients.43
In those with LBBB, CRT significantly reduced composite
adverse clinical events (RR, 0.64; 95% CI, 0.52 to 0.77;
P ¼ .00001). No benefit was observed for patients with
non-LBBB conduction abnormalities (RR, 0.97; 95% CI,
0.82 to 1.15; P ¼ .75). Specifically, there was no benefit
in patients with right bundle-branch block (RR, 0.91;
95% CI, 0.69 to 1.20; P ¼ .49) or nonspecific intraventric-
ular conduction delay (RR, 1.19; 95% CI, 0.87 to 1.63;
P ¼ .28). Overall, the difference in effect of CRT between
LBBB versus non-LBBB patients was highly statistically
significant (P ¼ .0001).43 Nevertheless, other studies have
shown that CRT is more likely to be effective in patients
with advanced HF and non-LBBB morphologies if they
have a markedly prolonged QRS duration21,30 (see RAFT
[Resynchronization-Defibrillation for Ambulatory Heart
Failure Trial]21 discussion below). Furthermore, patients
with QRS prolongation due to frequent right ventricular
apical pacing may benefit from CRT when other criteria
for CRT are met.23,25,48 No large trial has yet
demonstrated clinical benefit among patients without QRS
prolongation, even when they have been selected with
echocardiographic measures of dyssynchrony.49
The observed heterogeneity of response even among
those who would appear to be excellent candidates fore134 The Journal of Thoracic and Cardiovascular SurCRT also may result from factors such as suboptimal lead
location and the location of conduction block from fibrosis
in relation to the pacing site. Several recent studies have em-
phasized the importance of LV lead placement. For exam-
ple, wider LV–right ventricular lead separation has been
shown to provide better results.50 A subanalysis of
MADIT-CRT (Multicenter Automatic Defibrillator Implan-
tation Trial with Cardiac Resynchronization Therapy)20
showed that an apical LV lead position, as compared with
a basal or midventricular position, resulted in a significant
increased risk for HF or death.51
Clinical trials of resynchronization included mainly pa-
tients in sinus rhythm. However, prospective experience
among patients with permanent atrial fibrillation and with
decreased LV systolic function suggests that benefit may re-
sult from biventricular pacing when the QRS duration is
>120 ms, although it may be most evident in patients in
whom atrioventricular nodal ablation has been performed,
such that right ventricular pacing is obligate.24,26,52
The benefit of CRT in patients with atrial fibrillation
is more pronounced in those with depressed ejection
fraction.25 Similarly, patients receiving prophylactic ICDs
often evolve progressively to dominant ventricular pacing,
which may reflect both intrinsic chronotropic incompetence
and aggressive up-titration of beta-adrenergic–blocking
agents.
When device implantation or reimplantation is being
considered for patients who require ventricular pacing, it
is prudent to recall the results of the DAVID (Dual Chamber
and VVI Implantable Defibrillator) trial.53 In this trial, dual-
chamber rate-responsive pacing increased HF admissions
and mortality rate as compared to sinus rhythm. A cutoff
of approximately 40% right ventricular pacing was seen
as deleterious.54 Similarly, in a substudy from MADIT-II
(Multicenter Automatic Defibrillator Implantation Trial
II), patients who were right ventricular paced>50% of
the time had a higher rate of new or worsened HF than those
right ventricular paced 50% of the time.55
The major experience with resynchronization derives
from patients with NYHA class III symptoms of HF and
LVEF 35%. Patients with NYHA class IV symptoms of
HF have accounted for only 10% of all patients in clinical
trials of resynchronization therapy. These patients were
highly selected ambulatory outpatients who were taking
oral medications and had no history of recent hospitaliza-
tion.56 Although a benefit has occasionally been described
in patients with more severe acute decompensation that re-
quired brief positive intravenous inotropic therapy to aid di-
uresis, CRT is not generally used as a ‘‘rescue therapy’’ for
such patients. Patients with dependence on intravenous ino-
tropic therapy, refractory fluid retention, or advanced
chronic kidney disease represent the highest-risk population
for complications of any procedure and for early death after
hospital discharge, and they are also unlikely to receivegery c December 2012
Tracy et al Clinical Guidelinesa meaningful mortality risk benefit from concomitant defi-
brillator therapy.19,57
Patients with NYHA class IV HF symptoms who derive
functional benefit from resynchronization therapy may re-
turn to a better functional status, in which prevention of sud-
den death becomes a relevant goal. Even among the selected
NYHA class IV patients identified within the COMPAN-
ION trial,17 there was no difference in 2-year survival rate
between the CRT patients with and without backup defibril-
lation, although more of the deaths in the CRT-Pacemaker
group were classified as sudden deaths.56
Perhaps the most significant changes in the present doc-
ument compared to the 2008 DBTGuideline4 are the expan-
sion of the Class I recommendation for CRT to include
patients with LBBB, QRS duration 150 ms, and NYHA
class II and the addition of a Class IIb recommendation
for patients who have LVEF 30%, ischemic etiology of
HF, sinus rhythm, LBBB with a QRS duration of 150
ms, and NYHA class I symptoms. These recommendations
are based on 4 studies in which CRT was evaluated in pa-
tients with minimal or mild symptoms of HF in the setting
of low LVEF. These include MADIT-CRT, RAFT, RE-
VERSE (Resynchronization Reverses Remodeling in Sys-
tolic Left Ventricular Dysfunction), and MIRACLE ICD
II (Multicenter InSync ICD Randomized Clinical Evalua-
tion II), all of which are discussed in the following para-
graphs.20-22,58
MADIT-CRT20 randomized patients with NYHA class I
or II ischemic and NYHA class II nonischemic cardiomy-
opathy, LVEF 30%, and QRS duration 130 ms on
GDMT to CRT-D or ICD alone. Of note, only 15% of
the total cohort of patients were NYHA class I. The pri-
mary endpoint, a composite of death or HF event, was re-
duced by 34% by CRT-D (HR, 0.66), with comparable
benefit for both ischemic and nonischemic etiology of
HF. HF events were reduced by 41%, without significant
reduction in mortality rate. CRT-D therapy was demon-
strated to be of more benefit in women than in men (HR:
0.37 and 0.76, respectively) and in patients with QRS du-
ration 150 ms than in patients with QRS duration<150
ms (HR: 0.48 and 1.06, respectively).20 Patients with
LBBB had a significant reduction in ventricular tachycar-
dia, ventricular fibrillation, and death compared to non-
LBBB patients, who derived no benefit (HR: 0.47 and
1.24, respectively).10
RAFT21 reported the use of CRT-D in patients with
NYHA class II or class III ischemic or nonischemic cardio-
myopathy, LVEF 30%, and QRS duration 120 ms, as
compared to those treated with an ICD alone. The primary
outcome of death or hospitalization for HF occurred in 33%
of patients receiving CRT-D and in 40% of patients receiv-
ing ICD only. RAFT not only showed a significant reduction
in hospitalization for HF (HR, 0.68; 95% CI, 0.56 to 0.83;
P<.001) but also was the first study to show a statisticallyThe Journal of Thoracic and Carsignificant reduction in death (HR, 0.75; 95% CI, 0.62 to
0.91; P ¼ .003) in mildly symptomatic patients with
NYHA class II symptoms. However, CRT-D was associated
with a higher risk of adverse device- or implantation-related
complications at 30 days after implantation (P < .001)
compared with an ICD and no CRT. Patients with LBBB
had a better outcome than did non-LBBB patients, but the
statistical interaction between benefit and QRSmorphology
was weak in this trial (P¼ .046). CRT-D therapy was effec-
tive in patients with QRS duration 150 ms but of no ben-
efit in patients with QRS duration<150 ms (HR for QRS
duration 150 ms, 0.59; 95% CI, 0.48 to 0.73; HR for
QRS duration <150 ms, 0.99; 95% CI, 0.77 to 1.27;
P ¼ .002 for interaction). Thus, both MADIT-CRT and
RAFT showed benefit in NYHA class II patients treated
with CRT-D and demonstrated that the benefit was primar-
ily achieved in patients with QRS duration 150 ms and
LBBB.20,21
The REVERSE trial consisted of 610 patients. This
study assessed CRT-D therapy in patients with NYHA
class I or II HF symptoms on maximum medical therapy,
LVEF 40%, and QRS duration 120 ms followed for 12
months and showed that 16% of patients receiving CRT
and 21% without CRT worsened (P ¼ .10). The time
to first HF hospitalization was delayed in patients receiv-
ing CRT therapy (HR, 0.47). The primary echocardio-
graphic endpoint of ventricular remodeling assessed by
LV end-systolic volume index was significantly improved
(reduction in end-systolic volume index) in patients
treated with CRT therapy (P < .0001). REVERSE did
not report a mortality rate benefit of CRT-D therapy.22
The lack of reported mortality rate benefit may be related
to the higher ejection fraction enrollment criterion (LVEF
40%) and the relatively short-term follow-up (12
months).22
MIRACLE ICD II included patients with NYHA class II
HF on GDMT with LVEF 35% and QRS duration 130
ms who were undergoing implantation of an otherwise indi-
cated ICD.58 In these patients, CRT did not alter exercise
capacity but did result in significant improvement in cardiac
structure and function and composite clinical response over
6 months.
Analysis of the multiple clinical trials of CRT is compli-
cated because trials encompass a range of LVEFs in their
entry criteria, as well as a range of measured outcomes.
For mortality rate, the trials showing benefit in NYHA class
III and IV patients typically included those with LVEF
35%.22,58 For patients with NYHA class II, trials
showing mortality rate benefit included those with LVEF
30%.20,21 A mortality rate benefit with CRT has not
been shown for patients who are NYHA class I.21 In terms
of demonstrating improvement in cardiac function (eg, sig-
nificant reduction in LV size and improvement in ejection
fraction), trials have included patients with LVEF 35%diovascular Surgery c Volume 144, Number 6 e135
Clinical Guidelines Tracy et alwho are NYHA class III and IV.58 Similarly, for patients
with LVEF 40%, trials demonstrating improvement in
function have included those who are NYHA class I and
II.22 The congruence of results from the totality of CRT tri-
als with regard to remodeling and HF events provides evi-
dence supporting a common threshold of 35% for benefit
from CRT in patients with NYHA class II through IV HF
symptoms. Although there is evidence for benefit in both
CRT-D and CRT-Pacemaker patients with NYHA class III
and IV symptoms, for NYHA class I and II HF, all of the tri-
als tested only CRT-D and not CRT-Pacemaker, and as such,
recommendations for these classes of patients can be made
only for CRT-D.20-22,58
Taken together, the evidence from the randomized trials
of CRT-D in patients with reduced LVEF and NYHA class
I or II shows that CRT can provide functional improvement
and decrease the risk of HF events and composite out-
comes.20,22,58,59 Still, CRT-D also has been shown to de-
crease the mortality rate for patients with NYHA class II
but not for those who have NYHA class I HF.20,21 As
a result, the data support a Class I recommendation for
CRT implantation in patients with LBBB and QRS
duration 150 ms and NYHA class II. Because of the
lack of mortality rate benefit and smaller sample size, we
believe CRT may be considered for patients who have
LVEF <30%, ischemic etiology of HF, sinus rhythm,
LBBB with a QRS duration 150 ms, and NYHA class I
symptoms on GDMT (Class IIb; LOE: B).
For all patients, optimal outcomes with CRT require ef-
fective placement of ventricular leads, ongoing HFmanage-
ment with neurohormonal antagonists and diuretic therapy,
and in some cases, later optimization of device program-
ming, especially atrioventricular (A-V) and interventricular
(V-V) intervals.51-60
Consistent with entry criteria for studies upon which
these recommendations are based, CRT implantation should
be performed only when the LVEF meets guideline criteria
for patients with nonischemic cardiomyopathy who have re-
ceived>3 months of GDMT, or for patients with ischemic
cardiomyopathy>40 days after myocardial infarction re-
ceiving GDMTwhen there was no intervening revasculari-
zation, or>3 months if revascularization was performed. It
is assumed that the final decision to recommend CRTwill be
based on an assessment of LVEFmade after any appropriate
waiting period has concluded, during which GDMT has
been applied. Finally, the pivotal trials demonstrating the
efficacy of CRT took place in centers that provided exper-
tise in device and HF therapy both at implantation and dur-
ing long-term follow-up.
Two other organizational guidelines by the Heart Failure
Society of America61 and the European Society of Cardi-
ology62 have recently been published that address indica-
tions for CRT. For the patient categories in common
between the Heart Failure Society of America documente136 The Journal of Thoracic and Cardiovascular Surand the present focused update, there was a good deal of
concordance. Although there are many areas of agreement,
some differences exist between the present guideline and
the European Society of Cardiology document. One differ-
ence is that in the present guideline, CRT is recommended
in NYHA class I patients who have LVEF 30%, have
ischemic heart disease, are in sinus rhythm, and have
a LBBB with a QRS duration 150 ms (Class IIb;
LOE: C).20,21 There is no similar recommendation in
the European Society of Cardiology document. The
European Society of Cardiology recommendations
include patients with QRS duration <120 ms. We have
not recommended CRT for any functional class or
ejection fraction with QRS durations<120 ms. We also
have elected to consider the presence of LBBB versus
non-LBBB in the class of recommendations, on the basis
of perceived differential benefit by functional class, QRS
morphology, and QRS duration.
2.8. Pacemaker Follow-up
2.8.3. Remote Follow-up and Monitoring
Since the publication of the 2008 DBT guideline, impor-
tant changes have occurred related to follow-up and remote
monitoring of CIEDs.4,15,63 CIEDs include pacemakers,
ICDs, CRTs, implantable loop recorders, and implantable
cardiovascular monitors. The current technology for
follow-up, evidence supporting its use, and clinical practice
of CIED monitoring have evolved. Routine in-person office
follow-up supplemented by transtelephonic monitoring
with limited remote follow-up for pacemakers was the stan-
dard approach before 2008.4,15 Transtelephonic monitoring,
with monitors that transmit the patient’s heart rhythm by
converting electrocardiographic information to sound and
transmitting it via telephone lines to a decoding machine
that then converts the sound back into a rhythm strip, is
now a dated technique4,15,63 because it allows for limited
monitoring of heart rate, rhythm, and battery status of
only pacemakers.63
Contemporary remote monitoring uses bidirectional te-
lemetry with encoded and encrypted radiofrequency sig-
nals, allowing transmission and receipt of information
from CIEDs (pacemakers, ICDs, CRTs, implantable loop
recorders, and implantable hemodynamic monitors).63
All major CIED manufacturers have developed proprietary
systems to allow patients to have their devices interrogated
remotely, and many use wireless cellular technology to ex-
tend the bidirectional telemetry links into the patient’s lo-
cation.15,63 The information is analyzed, formatted, and
transmitted to a central server, where it can be accessed
by clinicians through the Internet. Information provided
through remote follow-up includes virtually all of the
stored information that would be obtained in an in-office
visit, including battery voltage, charge time in ICDs,gery c December 2012
TABLE 3. Minimum frequency of CIED in-person or remote
monitoring*
Type and frequency Method
Pacemaker/ICD/CRT
Within 72 h of CIED implantation In person
2-12 wk postimplantation In person
Every 3-12 mo for pacemaker/CRT-Pacemaker In person or remote
Every 3-6 mo for ICD/CRT-D In person or remote
Annually until battery depletion In person
Every 1-3 mo at signs of battery depletion In person or remote
Implantable loop recorder
Every 1-6 mo depending on patient symptoms
and indication
In person or remote
Implantable hemodynamic monitor
Every 1-6 mo depending on indication In person or remote
More frequent assessment as clinically indicated In person or remote
CIED, Cardiovascular implantable electronic device; CRT, cardiac resynchronization
therapy; CRT-D, cardiac resynchronization therapy defibrillator; CRT-Pacemaker,
cardiac resynchronization therapy pacemaker; ICD, implantable cardioverter-defi-
brillator. Modified fromWilkoff et al.15 *More frequent in-person or remote monitor-
ing may be required for all the above devices as clinically indicated.
Tracy et al Clinical Guidelinespercent pacing, sensing thresholds, automatically mea-
sured pacing thresholds when available, pacing and shock
impedance, and stored arrhythmia events with electro-
grams.15,63 CIEDs with wireless telemetry capability may
be programmed at a face-to-face evaluation to subse-
quently send automatic alerts for a variety of issues that
the clinician deems significant, such as abnormal battery
voltage, abnormal lead parameters, or increased duration
or frequency of arrhythmia episodes.15 Remote transmis-
sions can be made at predetermined intervals or at un-
scheduled times for prespecified alerts related to device
function or activated by the patient for clinical reasons.63
A detailed description of techniques, indications, person-
nel, and frequency has been published as a consensus
document.15
Several prospective randomized trials have been con-
ducted evaluating the effect of remote monitoring on clin-
ical outcomes64-67 since the publication of the 2008 DBT
Guideline.4 Collectively, these trials have demonstrated
that remote monitoring is a safe alternative to office visits
to evaluate CIEDs. Compared with in-person office visits
to evaluate CIEDs, remote monitoring leads to early dis-
covery of clinically actionable events, decreased time to
clinical decision in response to these events, and fewer of-
fice visits.64-67 Long-term survival rates of patients mon-
itored remotely with ICDs in a practice setting compare
favorably with survival rates of patients in clinical
trials.68
Current suggestions for the minimum frequency of in-
office and remote monitoring of patients with CIEDs are
summarized in Table 3.15 Issues such as lead malfunction,
unreliable battery life indicators, and other device or lead
recalls influence clinical decisions, which may change the
appropriate minimum follow-up.The Journal of Thoracic and CarPRESIDENTS AND STAFF
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APPENDIX 3. Indications for CRT therapy—algorithm
CRT, Cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy defibrillator; GDMT, guideline-directed medical therapy; ICD, implantable cardioverter-
defibrillator; LV, left ventricular; LVEF, left ventricular ejection fraction; LBBB, left bundle-branch block; MI, myocardial infarction; and NYHA, New York Heart Association.
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